skip to content

Other

AstraZeneca receives positive EU CHMP opinion for asthma treatment

10 November 2017 13:06

AstraZeneca has confirmed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending the marketing authorisation of benralizumab.

The opinion was formed around benralizumab being used as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting b-agonists.

Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said:

"This positive recommendation is an important step towards providing a next-generation treatment for severe, uncontrolled asthma patients with an eosinophilic phenotype. Benralizumab has the potential to make a real difference to patients with its combination of efficacy, speed of onset, convenience and the ability to reduce oral steroid use."

At 1:06pm: (LON:AZN) AstraZeneca PLC share price was -97.5p at 4864.5p

Story provided by StockMarketWire.com

Related Company: AZN

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.